Corcept Therapeutics Incorporated (CORT): Marketing Mix Analysis [Apr-2026 Updated]

You're digging into Corcept Therapeutics Incorporated right now, and frankly, late 2025 is a pivotal moment where their entire valuation narrative is on the line. We have one commercial product, Korlym, driving revenue that's guiding between $800 million and $850 million for the full year, but the real action is the looming December 30, 2025, PDUFA date for their next big hope, Relacorilant. I've broken down the four P's-from the high-cost specialty distribution kinks they are actively fixing to the aggressive promotion supporting that revenue target-so you get a clear-eyed view of the near-term risks and the massive potential catalyst ahead. Dive in below to see the full marketing mix strategy.

Corcept Therapeutics Incorporated (CORT) - Marketing Mix: Product

You're looking at the core offerings of Corcept Therapeutics Incorporated as of late 2025. The company's product strategy centers on developing medications that modulate the effects of the hormone cortisol across several serious disorders. Right now, the entire commercial foundation rests on one approved product, but the near-term future is defined by a critical regulatory decision.

Korlym (mifepristone) remains the sole commercial product for Corcept Therapeutics Incorporated. It is approved for treating Cushing's syndrome, also known as endogenous hypercortisolism. This product drives the current financial performance. For the third quarter of 2025, Korlym generated revenues of $207.6 million. Over the first nine months of 2025, sales reached $559.3 million, marking an increase of about 13.4% year-over-year. Management has raised the full-year 2025 revenue guidance to a range between $800 million and $850 million. One model estimated full-year 2025 sales to hit $857.1 million. The patient base is growing; approximately 3,250 paying patients were on the drug at the end of the third quarter of 2025. Tablet shipments in the third quarter increased by 42.5% over the prior year, hitting an all-time high for the quarter. To support this, the sales force expanded significantly to 150 clinical specialists from just 60 at the start of the year. You should note the impact of the Authorized Generic (AG); in the third quarter, about 70% of the business was on the AG, which carries about a 30% discount to the list price of Korlym.

The next major product event is the Prescription Drug User Fee Act (PDUFA) date for relacorilant, a selective cortisol modulator, which is set for December 30, 2025, for the hypercortisolism indication. This molecule is designed to modulate cortisol activity by selectively binding to the glucocorticoid receptor (GR) without affecting other hormone receptors. The NDA for this indication is supported by data from the pivotal Phase 3 GRACE trial, the Phase 3 GRADIENT long-term extension study, and a Phase 2 trial.

Corcept Therapeutics Incorporated is also pursuing oncology expansion with relacorilant. The New Drug Application (NDA) for use in platinum-resistant ovarian cancer (PROC) has a PDUFA date of July 11, 2026. Data from the pivotal ROSELLA trial in PROC showed that adding relacorilant to nab-paclitaxel resulted in a 30 percent reduction in the risk of disease progression (Hazard Ratio: 0.70; p-value: 0.0076) and a 31 percent reduction in the risk of death (Hazard Ratio: 0.69; p-value: 0.0121) versus nab-paclitaxel alone. For patients with prior PARP inhibitor treatment, the median Progression-Free Survival (PFS) was 7.36 months with the combination. The company has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the ovarian cancer indication. Analysts have projected relacorilant's future annual revenue from hypercortisolism alone could reach between $3 billion and $5 billion.

The company is building diversification through its early-stage pipeline, all focused on cortisol modulation:

• Dazucorilant (ALS): Phase II DAZALS trial showed an 84% reduction in the risk of death at one year compared to placebo (p=0.0009). A Phase 3 trial is planned for 2026.
• Miricorilant (MASH/NASH): A Phase 1b study demonstrated rapid reduction in liver fat. The Phase 2b MONARCH trial is currently ongoing.

Here is a quick look at the key product assets and their current development status:

The company's focus is clearly on leveraging its core competency in cortisol modulation. You can see the operational scale-up, like the sales force growing from 60 to 150, is designed to support the current product while preparing for the potential launch of relacorilant, which could redefine the revenue profile by 2026. If onboarding takes 14+ days, churn risk rises, which is why the specialty pharmacy transition, with a new vendor starting October 1st, is so important for meeting demand.

Finance: draft 13-week cash view by Friday.

Corcept Therapeutics Incorporated (CORT) - Marketing Mix: Place

You're looking at the logistics backbone for Corcept Therapeutics Incorporated's specialty products, which, as of late 2025, is undergoing a significant structural shift to handle accelerating demand.

Distribution for Corcept Therapeutics Incorporated's therapies is strictly channeled through a limited specialty pharmacy network, which is the standard operating procedure for high-cost, rare-disease pharmaceuticals requiring specialized handling and patient support.

Corcept Therapeutics Incorporated is actively transitioning away from a single-vendor approach to a multi-vendor specialty pharmacy model. This strategic pivot directly addresses the fulfillment capacity bottlenecks experienced during the first half of 2025, specifically impacting Q1 and Q2 2025 prescription fulfillment.

The company brought a new partner, Curant Rare, online in Q4 2025 to bolster support for rising prescription volume. The announcement of this partnership was made on October 1, 2025. This move was necessary partly because the previous vendor, Optime Care, announced it would discontinue servicing Corcept Therapeutics Incorporated prescriptions due to its preference for exclusive relationships. Corcept Therapeutics Incorporated management confirmed that the addition of Curant Rare on October 1, along with plans to add others in the coming months, is intended to allow the company to meet the increasing demand seen every month.

The operational constraints were significant enough to cause a downward revision of the full-year 2025 revenue guidance to $800-$850 million, down from earlier guidance of $900-$950 million. Analysts estimated that these pharmacy fulfillment constraints limited Q2 2025 revenue growth by approximately $15 million. The underlying demand, however, showed robust growth; prescription volume grew by +49% in Q2 2025 versus Q2 2024, with unfulfilled orders suggesting a pro forma growth rate closer to +60%. The Q3 2025 revenue reported was $207.6 million.

The distribution strategy is fundamentally designed to ensure comprehensive patient support, which is critical for adherence, and to manage the drug's mandated Risk Evaluation and Mitigation Strategy (REMS) requirements. This high-touch model is integral to the patient journey for these specialized treatments.

Here's a look at the key operational metrics tied to the distribution strategy through late 2025:

The focus remains on scaling the logistics infrastructure to match the underlying prescription demand. You can see the progression of the fulfillment capacity challenge:

• Distribution relies on specialty pharmacy and specialty distributor support.
• Original vendor (Optime Care) had difficulty meeting demand in Q1, Q2, and Q3 2025.
• New partner Curant Rare added on October 1, 2025.
• Corcept Therapeutics Incorporated plans to add others in the coming months following October 2025.
• Strategy is designed to manage the drug's Risk Evaluation and Mitigation Strategy (REMS).

Finance: draft 13-week cash view by Friday.

Corcept Therapeutics Incorporated (CORT) - Marketing Mix: Promotion

Promotion for Corcept Therapeutics Incorporated (CORT) centers on communicating the expanded utility of its current product and the transformative potential of its late-stage pipeline assets to key stakeholders, including physicians, payers, and investors.

Aggressive sales force expansion is underway to increase physician visibility and drive new Korlym prescriptions. The company has significantly scaled its commercial footprint to address the broader patient population identified through recent studies. The sales team increased to 150 clinical specialists as of the third quarter of 2025, up from 60 at the start of the year. Some reports indicated a trajectory aiming for 175 specialists by the end of 2025. This investment is quantified by analyst estimates suggesting each new sales representative could generate $2-$3 million in annual revenue.

The promotional focus leverages the CATALYST study data, which suggests a larger patient population for hypercortisolism, especially in hard-to-treat diabetics. This data is crucial for expanding the diagnosis rate beyond the most obvious cases. Key findings being promoted include:

• 24 percent of patients with difficult-to-control type 2 diabetes were found to have hypercortisolism.
• The prevalence phase screened 1,057 patients across 36 sites in the United States.
• In the treatment phase, Korlym use resulted in a 1.47% reduction in hemoglobin A1c over 24 weeks.

This educational push is driving prescription volume, evidenced by a 42.5% increase in Korlym tablet shipments in the third quarter of 2025 compared to the third quarter of 2024. As of September 30, 2025, approximately 3,250 paying patients were on Korlym therapy.

Key promotional catalysts are the upcoming FDA decisions for Relacorilant in hypercortisolism and ovarian cancer. These regulatory milestones represent the next major commercial inflection points, driving investor and physician anticipation. The company is actively preparing for these potential launches, as reflected in the rise of operating expenses to $197.4 million in the third quarter of 2025, up from $135.9 million year-over-year, largely due to launch preparations.

The critical dates for these catalysts are:

Furthermore, the European Marketing Authorization Application (MAA) for ovarian cancer is expected to receive a decision by year-end 2026.

Investor relations heavily promotes the pipeline's potential to generate $3 billion to $5 billion in annual revenue in the next 3-5 years. This projection is specifically tied to the potential peak sales for Relacorilant in the hypercortisolism market, signaling the long-term commercial opportunity beyond the current Korlym revenue base. This optimism underpins the company's financial positioning, with a revised 2025 revenue guidance set between $800 million to $850 million as of the third quarter update. The company maintained a strong liquidity position with $524.2 million in cash and investments at September 30, 2025.

The promotional narrative is supported by strong top-line performance, even with operational constraints. Third quarter 2025 revenue reached $207.6 million. The company is actively managing fulfillment capacity, having brought a second specialty pharmacy online starting October 1st, to capture the demand that previously resulted in an estimated $15 million in lost potential revenue during the second quarter.

Corcept Therapeutics Incorporated (CORT) - Marketing Mix: Price

You're looking at the pricing structure for Corcept Therapeutics Incorporated's main product, Korlym, and it's definitely set at the high end of the specialty drug spectrum. This pricing reflects the drug's niche indication for hypercortisolism (Cushing's Syndrome) and the value delivered to patients who have few other options.

Korlym is a high-cost specialty drug, with an estimated annual cost per patient around $\mathbf{\$180,000}$. To give you a concrete reference point for the list price, the Average Wholesale Price (AWP) for a 28-count bottle of Korlym 300mg was approximately $\mathbf{\$23,241.12}$ as of early 2024. That's a big number, but Corcept Therapeutics Incorporated's financial structure shows they maintain significant pricing leverage on what they actually keep.

Here's a quick look at how the pricing power translates into financial performance metrics as of late 2025:

Corcept Therapeutics Incorporated's gross margin is exceptionally high, reported at $\mathbf{98.3\%}$, indicating strong pricing power on the net selling price. That high margin is key because it funds the significant operating expenses seen in 2025, which are largely tied to preparing for the anticipated launches of relacorilant in hypercortisolism and platinum-resistant ovarian cancer. Full-year 2025 revenue guidance was revised to a range of $\mathbf{\$800 \text{ million to } \$850 \text{ million}}$, reflecting strong demand despite earlier distribution issues.

To manage market dynamics, especially with generic competition looming, Corcept Therapeutics Incorporated employs a dual-product strategy involving the branded drug and an authorized generic (AG) version of mifepristone. This strategy helps manage formulary access and provides a lower-priced alternative for certain patients.

The authorized generic component is a significant part of the current pricing mix:

• The authorized generic (AG) share reached the low $\mathbf{70\text{s}}\%$ of total volume in the third quarter of 2025.
• The net price for the AG product represents about a $\mathbf{30\%}$ discount compared to Korlym's list price.
• Management expects the AG share to creep up to around $\mathbf{75\%}$ by the end of 2025.

This strategy allows Corcept Therapeutics Incorporated to capture a large portion of the market volume through the lower-priced AG while maintaining a higher net price realization on the remaining branded Korlym sales, which is crucial for maximizing revenue while addressing payer demands for cost concessions. Finance: draft 13-week cash view by Friday.